Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

A Phase 1, Open-Label Study of MGD013, a Bispecific DART ® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jie Wang, MD, Adam S. Asch, MD, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA, Andrew Weickhardt, MBBS(Hons) FRACP DMedSc, Monika Tomaszewska-Kiecana, Monika Dlugosz-Danecka, MD PhD, Halyna Pylypenko, MD, Shakeela Bahadur, MD, Susanna Ulahannan, MD MMed, Janine Koucheki, Jichao Sun, PhD, Hua Li, Francine Chen, MD, Xiaoyu Zhang, John Muth, MS, Patrick Kaminker, PhD, Paul Moore, PhD, Bradley James Sumrow, MD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-139868

Published: 2020

Journal Articles

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

David A Sallman, MD, Adam S. Asch, MD, Monzr M. Al Malki, MD, Daniel J. Lee, MD, William B. Donnellan, MD, Guido Marcucci, MD, Suman Kambhampati, MD, Naval G. Daver, MD, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Joanna Van Elk, Ming Lin, PhD, Jens-Peter Volkmer, MD, Chris H Takimoto, MD PhD, Mark Chao, MD PhD, Paresh Vyas, MD PhD

Blood (2019) 134 (Supplement_1): 569.

https://doi.org/10.1182/blood-2019-126271

Published: 2019

Journal Articles

A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy

Blood (2019) 134 (Supplement_1): 3919.

https://doi.org/10.1182/blood-2019-130635

Published: 2019

Journal Articles

Key Barriers to Clinical Trial Enrolment: A Survey of Clinical Trial Staff at an NCI Designated Cancer Center

Amany R. Keruakous, MD, Adam S. Asch, MD

Blood (2019) 134 (Supplement_1): 5864.

https://doi.org/10.1182/blood-2019-126257

Published: 2019

Journal Articles

A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory Acute Myeloid Leukaemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy

William B. Donnellan, MD, Ehab L. Atallah, MD, Adam S. Asch, MD, Manish R Patel, MD, Julie Charlton, Alexander MacDonald, Elena Young, Elizabeth Sainsbury, Donald Strickland, MD, Suzanne Jones, PharmD, Philip Overend, Carrie A. Adelman, Jon Travers, PhD, Simon Smith, PhD, J. Elizabeth Pease, PhD, Wolfram Brugger, MD PhD

Blood (2018) 132 (Supplement 1): 4064.

https://doi.org/10.1182/blood-2018-99-118465

Published: 2018

Journal Articles

Thrombocytopenia Is a Biomarker for Response in Patients Treated with Anti PD-1/Pdl-1 Therapy

Hussein Assi, MD, Sami Ibrahimi, MD, Michael Machiorlatti, Sara K. Vesely, PhD MPH, Adam S. Asch, MD

Blood (2018) 132 (Supplement 1): 1138.

https://doi.org/10.1182/blood-2018-99-117764

Published: 2018

Journal Articles

Role of Somatic Mutations and Clonal Thrombopoiesis in Immune Thrombocytopenia

Sami Ibrahimi, MD, James George, MD, Patrick M Gaffney, MD, Sara K. Vesely, PhD MPH, Adam S. Asch, MD

Blood (2018) 132 (Supplement 1): 130.

https://doi.org/10.1182/blood-2018-99-111413

Published: 2018

Journal Articles

Preliminary Safety and Efficacy Results with an Intermittent Schedule of the PI3kδ Inhibitor ME-401 Alone or in Combination with Rituximab for B-Cell Malignancies

Andrew D. Zelenetz, MD PhD, Jacob D. Soumerai, MD, Deepa Jagadeesh, MD MPH, Nishitha Reddy, MD, Anastasios Stathis, MD, Adam S. Asch, MD, Huda S. Salman, MD, Vaishalee P. Kenkre, MD, Haresh Jhangiani, MD MBA, Alexia Iasonos, PhD, Patel Krish, MD, Richard G Ghalie, MD MBA, John M. Pagel, MD PhD

Blood (2018) 132 (Supplement 1): 2893.

https://doi.org/10.1182/blood-2018-99-115670

Published: 2018

Journal Articles

Prognostic Significance of Weight Loss and BMI during Induction Chemotherapy of Newly Diagnosed Acute Myeloid Leukemia (AML) Patients

Zachary Smith, MD, Gabriel Vidal, MD, Michael Machiorlatti, MS, Sara K. Vesely, PhD, Summer Frank, MPH, Adam S. Asch, MD, Jennifer L Holter-Chakrabarty, MD, Mohamad Khawandanah, MD, Mohamad Cherry, MD

Blood (2015) 126 (23): 5625.

https://doi.org/10.1182/blood.V126.23.5625.5625

Published: 2015

Journal Articles

Phase II Trial Daily Pulse Interleukin-2 Therapy with Famotidine during Marrow and Lymphocyte Recovery in Acute Myeloid Leukemia: LJCC 0605

Reed Friend, MD, Ridas Juskevicius, MD, Lauren Salmon, DO, Hemant S. Murthy, MD, James Xenakis, Adam S. Asch, MD, Paul Walker, MD

Blood (2015) 126 (23): 3783.

https://doi.org/10.1182/blood.V126.23.3783.3783

Published: 2015

Journal Articles

Impact of Insurance Status on the Day of Admission and Clinical Outcome on Acute Myeloid Leukemia (AML)Patients

Bilal Ahmad, MD, Hossein Maymani, MD, Haseeb Saeed, MD, Mohamad Khawandanah, MD, Samer A Srour, MB ChB, Michael G Machiorlatti, MS, Adam S. Asch, MD, Mohamad Cherry, MD

Blood (2014) 124 (21): 2274.

https://doi.org/10.1182/blood.V124.21.2274.2274

Published: 2014

Journal Articles

Time from Hospital Admission to Induction Chemotherapy Adversely Affects Outcomes in Patients with Acute Myeloid Leukemia

Hossein Maymani, MD, Bilal Ahmad, MD, Michael G Machiorlatti, MS, Sara K. Vesely, PhD, Samer A Srour, MB ChB, George Selby, MD, Adam S. Asch, MD, Mohamad Cherry, MD

Blood (2014) 124 (21): 1289.

https://doi.org/10.1182/blood.V124.21.1289.1289

Published: 2014

Journal Articles

Western Intravascular Lymphoma (IVL): Case Series of Published Reports Between 1994-2014

Mohamad Khawandanah, MD, Bilal Ahmad, MD, Fahad Khan, MD, Jennifer L. Holter Chakrabarty, MD, Carrie Yuen, MD, George Selby, MD, Adam S. Asch, MD, Mohamad Cherry, MD

Blood (2014) 124 (21): 5417.

https://doi.org/10.1182/blood.V124.21.5417.5417

Published: 2014

Journal Articles

Mediastinal Germ Cell Tumor and Acute Megakaryoblastic Leukemia– a Systematic Review of Cases Reported in the Literature

Sonia John, MD, Mohammed Abdul Muqeet Adnan, MD, Mohammad O. Khalil, MD, George Selby, MD, Adam S. Asch, MD, Mohamad Cherry, MD, Mohamad Khawandanah, MD

Blood (2014) 124 (21): 3694.

https://doi.org/10.1182/blood.V124.21.3694.3694

Published: 2014

Journal Articles

A Multicenter Phase II Study Of Bendamustine In Combination With Rituximab In Older Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

Steven I. Park, MD, Kristy L. Richards, MD PhD, Adam S. Asch, MD, Oludamilola Olajide, MBBS, Allison M. Deal, MS, Anastasia Ivanova, PhD, James G. Wall, MD, Anna L. Sobol, MD, Matthew C. Foster, MD, Hyman B. Muss, MD, Thomas C. Shea, M.D.

Blood (2013) 122 (21): 1791.

https://doi.org/10.1182/blood.V122.21.1791.1791

Published: 2013

NARROW

A Phase 1, Open-Label Study of MGD013, a Bispecific DART ® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

A Phase I/II Study of AZD2811 Nanoparticles (NP) As Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refractory AML/MDS Patients Not Eligible for Intensive Induction Therapy

Key Barriers to Clinical Trial Enrolment: A Survey of Clinical Trial Staff at an NCI Designated Cancer Center

Thrombocytopenia Is a Biomarker for Response in Patients Treated with Anti PD-1/Pdl-1 Therapy

Role of Somatic Mutations and Clonal Thrombopoiesis in Immune Thrombocytopenia

Preliminary Safety and Efficacy Results with an Intermittent Schedule of the PI3kδ Inhibitor ME-401 Alone or in Combination with Rituximab for B-Cell Malignancies

Prognostic Significance of Weight Loss and BMI during Induction Chemotherapy of Newly Diagnosed Acute Myeloid Leukemia (AML) Patients

Phase II Trial Daily Pulse Interleukin-2 Therapy with Famotidine during Marrow and Lymphocyte Recovery in Acute Myeloid Leukemia: LJCC 0605

Impact of Insurance Status on the Day of Admission and Clinical Outcome on Acute Myeloid Leukemia (AML)Patients

Time from Hospital Admission to Induction Chemotherapy Adversely Affects Outcomes in Patients with Acute Myeloid Leukemia

Western Intravascular Lymphoma (IVL): Case Series of Published Reports Between 1994-2014

Mediastinal Germ Cell Tumor and Acute Megakaryoblastic Leukemia– a Systematic Review of Cases Reported in the Literature

A Multicenter Phase II Study Of Bendamustine In Combination With Rituximab In Older Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only